INTRODUCTION
Mammalian cell proliferation is tightly regulated by the sequential activation of cyclin-dependent kinases (Cdks) (Sherr and Roberts, 1999) . The Cdk inhibitor, p27, was initially identified in cells arrested by transforming growth factor b (TGF-b), by contact inhibition, and by lovastatin (Polyak et al., 1994; Hengst et al., 1994; Slingerland et al., 1994; Koff et al., 1993) . p27 is ubiquitously expressed and binds cyclin-Cdk2 to inhibit kinase activity.
p27 is maximal in quiescence, and mitogen-stimulated p27 loss during G 0 to S phase progression leads to cyclin E-Cdk2 activation. Several mechanisms regulate p27 levels to control cell proliferation. p27 translation is maximal in G 0 and falls abruptly with G 0 exit and during G 1 progression (Gopfert et al., 2003; Hengst and Reed, 1996; Agrawal et al., 1996) . At least four pathways regulate p27 degradation. In late G 1 through S and into M phase, p27 is degraded by the SCF Skp2 ubiquitin ligase, whose interaction with p27 is activated by cyclin E-Cdk2-dependent p27 phosphorylation at T187 (Pagano et al., 1995; Sheaff et al., 1997; Vlach et al., 1997; Montagnoli et al., 1999) . In early G 1 , T187-independent p27 proteolysis occurs by both Skp2-dependent (Malek et al., 2001) and Skp2-independent (Hara et al., 2001) pathways. In early G 1 , p27 phosphorylation at S10 promotes p27-CRM1 binding and nuclear export (Rodier et al., 2001; Ishida et al., 2002; Connor et al., 2003) . Proteolysis of cytoplasmic p27 in G 1 involves KPC1 ubiquitin ligase (Hara et al., 2005; Kamura et al., 2004) . Rapid S10-independent p27 proteolysis may also occur in the nucleus in early G 1 (Rodier et al., 2001) . In quiescent cells, p27 proteolysis requires an intact p27-cyclin-Cdk binding motif (Besson et al., 2006) . p27 levels regulate cell proliferation and differentiation. p27 null animals exhibit multiorgan hyperplasia (Fero et al., 1996; Kiyokawa et al., 1996; Nakayama et al., 1996) , and p27 +/À heterozygous animals are tumor prone (Fero et al., 1998) . While normal quiescent epithelial tissues express high p27 (Catzavelos et al., 1997) , reduced p27 protein is observed in up to 60% of primary human breast and other cancers in association with poor patient outcome (Alkarain et al., 2004) . Several oncogenic pathways activate p27 proteolysis in cancers (Liang and Slingerland, 2003) . Human breast cancers frequently show EGFR overexpression or Her2/ErbB2 amplification (Tsutsui et al., 2002; Nicholson et al., 1990; Slamon et al., 1987) . Overexpression of EGFR or Her2 increases p27 proteolysis in cell lines (Lane et al., 2000; Yang et al., 2000; Lenferink et al., 2000) .
Activated EGFR family receptor tyrosine kinases (RTK) recruit and activate cSrc, and cSrc in turn further activates RTKs, stimulating cell proliferation (Ishizawar and Parsons, 2004) . Drug-mediated cSrc inhibition blocks the effects of EGFR and Her2 on cell proliferation (BelschesJablonski et al., 2001; Biscardi et al., 1999) . cSrc is also activated by liganded estrogen receptor (ER) in human breast cancer cells. Estrogen:ER binding stimulates rapid, transient recruitment of cSrc, Shc activation, and MAPK signaling (Migliaccio et al., 1996) . Estrogen:ER-stimulated Src further recruits RTKs, Her2, EGFR (Chu et al., 2005) , and IGF-1R (Song et al., 2004) , to promote cell cycle progression.
We recently demonstrated a novel Lyn-and Bcr-Ablmediated tyrosine phosphorylation of p27 that contributes to p27 proteolysis (Grimmler et al., 2007 [this issue of Cell] ). Up to 60% of human breast cancers express the ER, and in these, estrogen is mitogenic. Estrogen-stimulated breast cancer proliferation requires a rapid loss of p27 through proteolysis (Cariou et al., 2000) . Given the oncogenic role of Src in breast cancer and its rapid activation by RTKs and estrogen:ER, we investigated whether Srcmediated tyrosine phosphorylation of p27 may contribute to p27 proteolysis in breast cancer cell proliferation.
Here we present evidence that cSrc phosphorylates p27 on tyrosine 74 (Y74) and tyrosine 88 (Y88). p27 phosphorylation by Src reduced the cyclin E-Cdk2 inhibitory action of p27 in vitro. Src induction increased pT187p27 and reduced the t 1/2 of p27. cSrc activation was correlated with low nuclear p27 in primary human breast cancers. Mitogen stimulation of quiescent cells rapidly activated cSrc, and p27 binding to cSrc preceded loss of cyclin E-Cdk2 from p27 in late G 1 . These data support a model in which cSrc-mediated tyrosine phosphorylation of p27 reduces its inhibitory action on cyclin E-Cdk2, facilitating subsequent p27 proteolysis.
RESULTS

Src Phosphorylates p27 In Vitro
Estrogen stimulates quiescent ER-positive breast cancer cells to rapidly degrade p27 and enter cell cycle (Cariou et al., 2000) . Estrogen-bound ER stimulates rapid, transient cSrc activation (Migliaccio et al., 1996; Song et al., 2004) . To investigate if cSrc contributes to estrogen-mediated p27 proteolysis, we assayed if Src could phosphorylate p27. Purified recombinant activated Src phosphorylated recombinant His-p27, and this was inhibited by the Src inhibitor, PP1 ( Figure 1A ). Recombinant WT Src could also phosphorylate p27 (data not shown). To assay the relative contributions of three tyrosines, Y74, Y88, and Y89, to Src phosphorylation of p27, single, double, and triple p27 mutations were generated converting tyrosines to phenylalanine. Mutant p27 and p27WT were compared as substrates in Src kinase assays. Src autophosphorylation indicates equal Src input ( Figure 1B ). Radioactivity in p27 was quantitated by phosphoimager ( Figure 1C ). Srcmediated p27 phosphorylation was reduced by 36% and 33% in p27Y74F and p27Y88F, respectively, compared to p27WT, while that of p27Y89F was only reduced by 12% ( Figure 1C ). Loss of Y74 and Y88 (p27Y74FY88F) reduced p27 phosphorylation by Src by 78%. Thus, these two sites appear to be preferentially phosphorylated by Src in vitro ( Figure 1C ). Loss of potential to phosphorylate Y89 also reduced phosphorylation of Y74FY89F and Y88FY89F. Not all Src family kinases are expressed in mammary cells. Quantitative real-time PCR of Src, Yes, Fyn, and Lyn in three breast cancer lines, MCF-7, T-47D, and MDA-MB-361, showed that Yes expression was higher or comparable to that of cSrc. Fyn and Lyn mRNA were detectable but several logs lower in magnitude (see Figure S1 in the Supplemental Data available with this article online). As for Src, Yes kinase assays showed that phosphorylation of p27 by Yes was reduced by mutational loss of Y74 and Y88 phosphorylation, while Y89F only modestly attenuated phosphorylation by Yes ( Figures 1D  and 1E ).
Tyrosine-Phosphorylated p27 Is a Poor Inhibitor of Cyclin E-Cdk2
The crystal structure of p27-cyclin A-Cdk2 shows that Y74, Y88, and Y89 of p27 interact with Cdk2 and not with N-terminal truncated cyclin A. Y88 is buried in the catalytic cleft of Cdk2, but Y74 and, to a lesser extent, Y89 also form contacts with Cdk2 (Russo et al., 1996) . Since Y88 impedes ATP binding to Cdk2, structural data suggest that tyrosine phosphorylation of p27 would impair its inhibition of cyclin-bound Cdk2. To test this, increasing amounts of mock or Src-phosphorylated His-p27 were incubated with recombinant cyclin E-Cdk2, and Cdk2 activity was assayed. Src was inactivated by boiling the Src-p27 reactions, and mock-treated His-p27 was also boiled prior to addition to cyclin E-Cdk2 reactions. Tyrosinephosphorylated p27 (pY-p27) inhibited cyclin E-Cdk2 less efficiently than mock-phosphorylated p27 (Figure 2A ).
To assay whether the impaired inhibitory function of pY-p27 correlated with decreased association with cyclin E-Cdk2, p27 was reacted in vitro with either active recombinant Src or Src that had been heat inactivated prior to reaction with p27 (dead Src) or was subjected to a mock Src reaction. Only active Src treated p27 reacted with antiphosphotyrosine antibody 4G10 (apY-4G10, Figure 2B ). (A) His-p27WT was phosphorylated in vitro with activated Src. Mock-treated (p27) or Srctreated pY-p27 was incubated with cyclin ECdk2 and H1 kinase activity assayed. Equal input of mock versus Src treated p27 is shown. (B-E) (B) His-p27WT incubated without Src (no Src), with inactive Src (dead Src), and with active Src is shown. pY-p27 was precipitated with apY-4G10. Equal amounts of p27 from (B) were incubated with cyclin E-Cdk2. (C) p27, (D) Cdk2, and (E) cyclin E were precipitated and associated proteins blotted.
Because the in vitro Src kinase reaction was not complete, pY-p27 was isolated by immunoprecipitation with apY-4G10. Equal amounts of mock or Src-treated p27 were incubated with recombinant cyclin E and Cdk2. Mocktreated and dead-Src-treated p27 immunoprecipitates bound equal amounts of cyclin E and Cdk2, while pY-p27 precipitates bound less cyclin E and Cdk2 ( Figure 2C ). Less Src-phosphorylated pY-p27 was detected in Cdk2 and cyclin E immunoprecipitates compared to mock or untreated p27 ( Figures 2D and 2E) . Thus, the reduced cyclin E-Cdk2 inhibitory function of Src-phosphorylated p27 versus unphosphorylated p27 may result in part from its reduced steady-state binding to this cyclin-Cdk2 target.
Intracellular Tyrosine Phosphorylation of p27
We and others recently identified tyrosine-phosphorylated p27 in leukemic cells (Kardinal et al., 2006; Grimmler et al., 2007) . Bcr-Abl and Lyn kinases phosphorylated p27 predominantly at Y88 in vitro, and in K562 cells, Y88 was the major tyrosine phosphorylated site in p27 (Grimmler et al., 2007) . Because in vitro kinase assays showed that p27Y74F had reduced phosphorylation by Src, polyclonal antibody specific to Y74-phosphorylated p27 (p27pY74) was generated. ap27pY74 antibody recognized Srcphosphorylated His-p27WT but not His-p27Y74F (Figure 3A, left) , while apY-4G10 reacted with both p27WT and p27Y74F after Src kinase reactions in vitro ( Figure 3A , left).
To detect intracellular Y74 phosphorylation of p27, MCF-7 cells were cotransfected with constitutively active Src or empty vector and YFPp27. Tyrosine-phosphorylated p27 was detectable with apY-4G10 in p27 immunoprecipitates from Src-transfected but not from mocktransfected cells ( Figure 3A , middle). Similarly, p27pY74 was detected with ap27pY74 antibody only after cSrc transfection ( Figure 3A , right). Endogenous cellular p27pY74 was also detected with this antibody in the absence of exogenous Src (see Figure 5E ).
To test the preference of Src for the different p27 tyrosines in cells, activated Src and YFPp27WT, p27Y74F, p27Y88F, or p27Y89F were transfected into MCF-7. All p27 vectors were equally and stably overexpressed (Figure 3B) . p27 precipitates were immunoblotted and reacted with apY-4G10, ap27pY74, or antibody to total p27. Reactivity of p27WT with apY-4G10 and with ap27pY74 following Src cotransfection was attenuated by the Src inhibitor, PP1 ( Figure 3B ).
Transfected p27Y74F and p27Y88F immunoprecipitates were less reactive than YFPp27WT with apY-4G10, while apY-4G10 reactivity of p27Y89F was not detectably reduced ( Figure 3B ). Y74 phosphorylation was detected in p27Y88F, p27Y89F, and p27WT, but reactivity of ap27pY74 with p27Y74F showed no increase above nonspecific baseline ( Figure 3B ). Thus, Y74 and Y88 appear to be the dominant cSrc phosphorylation sites in vivo. Loss of Y89 phosphorylation may attenuate Y74 phosphorylation in vivo and lead to a compensatory increase in Y88 phosphorylation.
The effect of Src overexpression on p27-cyclin E-Cdk2 complexes was tested. Src transfection with or without PP1 treatment did not affect levels of cellular cyclin E and Cdk2 or overexpressed YFPp27 ( Figure 3C ). YFPp27WT immunoprecipitates contained less bound cyclin E and Cdk2 following Src transfection, and this was abrogated by PP1 ( Figure 3D ). Similarly, Src transfection modestly reduced p27 in Cdk2 precipitates, while Cdk2-bound cyclin E was unaffected ( Figure 3E ).
Src Effects on Cellular p27 Levels and Stability
Since experiments above involved overexpressed p27, which could overwhelm cellular p27 proteolysis, effects of Src on cellular p27 were assayed. cSrc siRNA or Src inhibition for 48 hr each increased cellular p27 (Figures 4A and 4B) .
Src is activated in MDA-MB-361 line due to Her2/ErbB2 activation (Belsches-Jablonski et al., 2001 ). p27 half-life was assayed by cycloheximide chase in asynchronous MDA-MB-361 and in cells treated with the Src family kinase inhibitor, AZD0530, for 6 hr. Src inhibition increased the p27 t 1/2 from 4.0 to 9.7 hr ( Figure 4C ).
To test further the effect of Src on p27 stability, inducible Src-expressing lines were generated. Cells were serum and estrogen deprived, and Src was induced or not with ponasterone A (PA) prior to readdition of estrogen. Estrogen stimulation alone, in the absence of added growth factors, had little effect on p27 levels over 6 hr; however, Src induction together with estrogen led to more rapid loss of p27 in two different Src-inducible MCF-7 clones (shown for MCF-pINDSrc2, Figure 4D ). Src induction reduced the p27 t 1/2 at 6 hr after estrogen addition to 5.8 hr compared to the p27 t 1/2 of 9.8 hr in controls treated with estrogen alone ( Figure 4E ). T187 phosphorylation of p27 was more readily detected when starved cells were treated with estrogen plus Src compared to estrogen alone ( Figure 4F ).
These findings support a model in which Src promotes p27 degradation by decreasing the inhibitory action of p27 on cyclin E-Cdk2, facilitating cyclin E-Cdk2-dependent p27 phosphorylation and SCF SKP2 -mediated p27 proteolysis.
cSrc-p27 Interaction Is Increased in Cancer Lines with Activated Src p27-bound cSrc was detected in three breast cancer lines, MCF-7, T-47D, and MDA-MB-361. Cells with higher cSrc activity had reduced p27 levels but higher p27-bound cSrc ( Figure 5A ).
In contrast to normal mammary epithelial cells in which p27 shows nuclear localization (Catzavelos et al., 1997) , T-47D and MDA-MB-361 have both nuclear and some cytoplasmic p27. p27-Src complexes were detected in nuclear fractions. Nuclear cSrc-p27 complexes were only minimally detectable in cells deprived of estrogen and growth factors in 0.1% cFBS for 48 hr (EÀ) but were readily detected in asynchronous cells in complete medium (E+) (data shown for T-47D, Figure 5B ). To confirm (A) His-p27WT or His-p27Y74F was reacted with Src in vitro. p27 precipitates were blotted with apY-4G10 or ap27pY74 (left). MCF-7 was transfected with YFPp27WT and empty PCI vector (Src À) or PCI-Src-Y530F (Src +). p27 precipitates were blotted with apY-4G10, stripped, and reprobed for p27 (middle panel). pY74p27 was detected in Src-transfected MCF-7 (right panel). (B) MCF-7 was cotransfected with YFPp27WT or mutant p27 with or without Src. pY-p27 was detected in p27 precipitates with apY-4G10 or ap27pY74. the nuclear localization of p27-Src complexes, p27S10A or p27WT was transfected into MCF-7 with or without transfection of Src. p27S10A is localized to the nucleus due to reduced nuclear export (Connor et al., 2003) . p27-bound Src was equally detected in p27S10A and p27WT complexes ( Figure S2 ).
cSrc-p27 Interaction Precedes p27 Loss in G 1 Progression Quiescent estradiol-depleted MCF-7 cells enter S phase within 12 hr of estrogen and insulin addition ( Figure 5C ) (Cariou et al., 2000) . cSrc was rapidly activated on G 0 exit, peaking at 1 hr, and fell to baseline by 3-6 hr (Figure 5D ). p27 levels fell during G 1 progression, while cSrc, cyclin E, and Cdk2 levels did not vary ( Figure 5C ). Rapid Src activation correlated with increased Src-p27 coprecipitation and preceded the reduction of total p27 and loss of p27-bound cyclin E and Cdk2 as cells entered S phase ( Figure 5D ).
To demonstrate Y74 phosphorylation of endogenous cellular p27, MCF-pINDSrc2 cells were estrogen deprived, and the Src was induced or not by PA. Cells were then treated with estrogen for 2 hr to stimulate endogenous cSrc. ap27pY74 precipitates were resolved and immunoblotted for p27 and Src. Following estrogen stimulation of starved cells, Y74 phosphorylation of cellular p27 was detected, and this was increased by Src induction ( Figure 5E ). Src-pY-p27 complexes were increased in Src-induced cells ( Figure 5E ).
cSrc Activation in Human Breast Cancers Is Correlated with Low Nuclear p27
To test if cSrc activation is associated with reduced p27 in primary human breast cancers, p27 and phosphorylated, activated cSrc (detected with an anti-pY416-Src antibody) were assayed by immunohistochemistry in 482 tumors. Thirty-seven percent showed reduced nuclear p27 levels. Little or no cSrc activation (score 0) was detected in 23% of tumors. cSrc activation (scores of 2 or 3) was detected in 39% of tumors. Normal mammary duct tissue controls present on all tissue microarrays showed no cSrc activation. The correlation of low p27 with cSrc activation and other clinical and pathologic variables is shown in Table 1 . As in prior studies, reduced p27 was strongly correlated with estrogen and progesterone receptor-negative status and was associated with increased tumor size, high tumor grade (a measure of dedifferentiation), and tumor invasiveness as indicated by more lymph nodes affected and intratumoral invasion of the lymphovascular spaces (LVI). Reduced p27 was statistically correlated with activated Src when all four Src scoring levels were used (p = 0.05), and this was more significant when Src activity was categorized as high (scores 2-3) or low (scores 0-1), p = 0.01 (Table 1) . Cancers with low p27 and high pY416-Src immunoreactivity (left panels) and high p27 with low pY416-Src (right panel) are shown in Figure S3 . 
Src Inhibition and Tamoxifen Cooperate to Inhibit Cell Cycle Progression
Tamoxifen is an ER-blocking drug that arrests sensitive ER-positive breast cancer cells in G 0 /G 1 by inhibiting estrogen-stimulated p27 proteolysis. p27 expression is required for arrest by tamoxifen (Cariou et al., 2000) . Overactivation of RTKs can confer antiestrogen resistance (Benz et al., 1992; Pietras et al., 1995; Donovan et al., 2001 ) and also recruit and activate Src Tice et al., 1999) . Since Src-dependent p27 phosphorylation impaired its cyclin-Cdk2 inhibitory action, we tested if Src inhibition could restore tamoxifen responsiveness to resistant cells. MDA-MB-361 has high cSrc activity ( Figure 5A ), fails to arrest upon estrogen deprivation, and is resistant to tamoxifen-mediated G 1 arrest. These cells showed only a partial G 1 arrest after 48 hr of treatment with an ER-saturating dose of tamoxifen. Increasing tamoxifen or treatment with the irreversible ER blocker, fulvestrant, failed to cause G 1 arrest (data not shown). AZD0530 (AstraZeneca Ltd.) is a potent, specific drug inhibitor of Src family kinases (Ple et al., 2004) in clinical trials for cancer in humans. While AZD0530 inhibits both Src family and Abl kinases, Abl is not expressed in breast cancers. Asynchronous MDA-MB-361 cells were treated with AZD0530, tamoxifen alone, or both together. The 1 mM dose of each drug caused partial G 1 arrest with the percent of S phase falling from 43% to 30% and 20%, respectively, after 48 hr. AZD0530 and tamoxifen together reduced the percent of S phase cells to 4% ( Figure 6A ). Each drug alone increased p27 by less than 2-fold, whereas both drugs together increase p27 >4-fold ( Figure 6B) . Cyclin E-Cdk2-bound p27 increased 2.3-fold with AZD0530, 1.7-fold with tamoxifen alone, and 5-fold with both drugs together ( Figure 6C ) with loss of cyclin E-cdk2 activity (data not shown). Thus, Src inhibition restored p27 action and tamoxifen-mediated G 1 arrest.
Src inhibition with AZD0530 also restored response to tamoxifen in two other ER-positive, partially resistant breast cancer lines, T-47D and BT474. In two lines with only modest Src activation (MCF-7 R and ZR75-1), AZD0530 did not augment tamoxifen responses (see Table S1 ).
DISCUSSION
Regulation of p27 Levels p27 is frequently inactivated in human cancers through accelerated p27 proteolysis or sequestration in the cytoplasm. Reduced p27 is an independent marker of poor breast cancer prognosis (Alkarain et al., 2004) . In normal cells, p27 levels fall rapidly as cells progress from G 1 to S phase. However, a major mechanism of p27 proteolysis involves its phosphorylation by the very kinase it inhibits. p27 acts both as an inhibitor and as a substrate of cyclin E-Cdk2 (Sheaff et al., 1997) . While cyclin E-Cdk2 phosphorylation of T187 targets p27 for SCF Skp2 -mediated proteolysis in late G 1 , mechanisms permitting initial cyclin E-Cdk2 activation in early G 1 despite the persistent abundance of its inhibitor have remained obscure. We and others have postulated that early G 1 phosphorylation events may reduce the affinity of p27 for cyclin E-Cdk2, promoting p27 dissociation from Cdk2, binding to CRM1, and export-driven proteolysis of p27 in the cytoplasm (Connor et al., 2003; Ishida et al., 2002; Hara et al., 2001 ). However, it has been difficult to provide definitive evidence for this in vivo. Our earlier work showed that TGF-b-resistant cells (Florenes et al., 1996; Ciarallo et al., 2002) and cancer cell lines that overexpress oncogenes including ILK, Her2, or MEK exhibit altered p27 phosphoisoforms with reduced cyclin E-Cdk2 inhibitory function (Radeva et al., 1997; Donovan et al., 2001; Ciarallo et al., 2002) . Such intermediate forms of p27 could facilitate the transition of p27 from inhibitor to substrate of cyclin E-Cdk2. Here we present evidence that Src-mediated tyrosine phosphorylation of p27 reduces its inhibitory function for cyclin E-Cdk2.
Src Activation in Cancer cSrc activates mitogenic signaling in normal and malignant cells to regulate cell proliferation, survival, metastasis, and angiogenesis (Ishizawar and Parsons, 2004; Thomas and Brugge, 1997) . Increased cSrc levels and/ or activity has been observed in many human cancers when compared to adjacent normal tissues, including breast, prostate, lung, colorectal, and ovarian carcinomas Irby and Yeatman, 2000; Biscardi et al., 2000) , and are often associated with increased disease stage (Frame, 2002) . We observed Src activation in 39% of 482 primary human breast cancers.
Src activation in cancers results from oncogenic activation of RTKs, including EGFR, Her2/ErbB2, IGF-1R, colony stimulating factor-1, and hepatocyte growth factor receptor. Reduced phosphorylation of its negative regulatory site, SrcY530, can also activate Src . Activating Src mutations are rare in human cancers and in colon cancer correlate with metastatic progression (Irby et al., 1999) . EGFR and Her2/ErbB2 both bind Src to catalyze mutual kinase activation. cSrc and EGFR family members are frequently overexpressed in primary human breast cancers (Ishizawar and Parsons, 2004) .
Src Regulates p27
Here we demonstrate cSrc-mediated p27 phosphorylation in vitro and in vivo at both Y74 and Y88. Mutation converting p27 Y89 to F reduced in vitro Src phosphorylation of p27 by only 12%, and p27Y89F cotransfected with Src showed no reduction in reactivity with apY-4G10 antibody in vivo compared to p27WT. While loss of Src phosphorylation of Y89 showed little effect in vivo, this site may modulate phosphorylation of Y74 and Y88.
Both putative tyrosine phosphorylation sites, p27Y74 and p27Y88, form contacts with Cdk2. The partial crystal structure of cyclin A-Cdk2-bound p27 reveals that the region between Y74 and Y88 of p27 forms a clamp around the N lobe of Cdk2 (Russo et al., 1996) . Y74 is partially buried in the N-terminal b sheet of Cdk2, forming hydrophobic interactions with L25, V30, L67, and V79 on the outer surface of the Cdk2 N lobe. The aromatic ring of p27Y88 forms van der Waals contacts to F80, F82, and L134 of Cdk2, and its hydroxyl group makes two hydrogen bonds to Cdk2 E81 and L83 (Russo et al., 1996) . The side chain of p27Y88 occupies the catalytic cleft of Cdk2 and mimics the contacts made by the purine base of ATP (Russo et al., 1996) . NMR data indicate that Y88 phosphorylation of p27 ejects the 3 10 helix from the catalytic cleft of Cdk2, but this phosphorylation alone did not disrupt p27 binding to cyclin A-Cdk2 (Grimmler et al., 2007) . This would explain the reduced inhibitory action of p27 toward cyclin E-Cdk2 following Src kinase pretreatment in vitro.
While Abl and Lyn appear to predominantly phosphorylate Y88, both Y74 and Y88 were phosphorylated by Src. Src-phosphorylated p27 showed a decreased steadystate association with cyclin E-Cdk2 both in vitro and following cotransfection of p27WT with activated Src in vivo. Phosphorylation of Y74 together with Y88 may not only mediate loss of p27 inhibitory activity against cyclin E-Cdk2 but also promote dissociation of p27 from the complex. Thus, different tyrosine kinases may have different consequences in vivo on p27 function and stability. Further studies will be required to elucidate the full structural implications of these tyrosine phosphorylation events on p27 function and to define the profile of tyrosine kinases that regulate these sites in vivo in response to mitogen stimulation. In certain cancers, constitutive Y88 phosphorylation, without concurrent Y74 phosphorylation, may permit activation of p27-associated cyclinCdk2. NMR structural data support this model (Grimmler et al., 2007) .
Estrogen:ER binding has been shown to recruit Src leading to MEK activation (Migliaccio et al., 1996; Song et al., 2004) , and estrogen also reduces p27 (Cariou et al., 2000) . The present data suggest that estrogendependent Src activation regulates p27 proteolysis. Src inhibition and siRNA increased cellular p27. Moreover, both cell lines and primary breast cancers with activated Src showed reduced p27. Src was rapidly activated by mitogen stimulation, and cellular p27-Src coprecipitation preceded the reduction of p27 and loss of cyclin E-Cdk2 from p27 prior to S phase entrance. Src inhibition prolonged the p27 half-life, and Src induction increased cellular p27pY74 and p27pT187 and reduced p27 half-life. These data support a model in which tyrosine phosphorylation of p27 by Src would reduce p27-mediated inhibition of cyclin E-Cdk2, liberating this kinase to phosphorylate its approximated inhibitor at T187, promoting p27 ubiquitination by SCF Skp2 and its degradation (Pagano et al., 1995; Sheaff et al., 1997; Carrano et al., 1999) . Tyrosine phosphorylation of p27 would thus regulate the transition of p27 from inhibitor to substrate of cyclin-Cdk2. p27 phosphorylation at T187 by cyclin A-Cdk2 in vitro was enhanced by prior Abl-phosphorylation of p27 and followed a pseudounimolecular mechanism; thus, pY-p27 appears to be more readily phosphorylated by cyclin-Cdk2 compared to nonphosphorylated p27 (Grimmler et al., 2007) . Src transfection in NIH3T3 and Rat-1 fibroblasts also increased Cdk2 activity and reduced p27 (Riley et al., 2001; Johnson et al., 1998) . Moreover, induced overexpression of dominant-negative Src increased p27 t 1/2 in MCF-7 (Gonzalez et al., 2006) . The role of cYes in response to RTKs and estrogen is less well characterized than that of cSrc. Given our observation that cYes can also phosphorylate p27 in vitro, the potential for cooperative effects of cYes and cSrc on p27 function warrants further investigation.
A Role for Src Inhibitors in Treatment of Antiestrogen-Resistant Breast Cancer ER blockade by tamoxifen or estrogen deprivation by aromatase inhibitors is of therapeutic utility in a majority of breast cancers that express the ER. p27 is required for G 1 arrest by tamoxifen or estrogen deprivation (Cariou et al., 2000) . Despite initial responses, the development of antiestrogen resistance limits treatment efficacy. EGFR and Her2/ErbB2 overexpression can confer tamoxifen resistance in cultured lines (Benz et al., 1992; Pietras et al., 1995; Donovan et al., 2001) . Since these RTKs activate Src and given our observation that Src impairs the Cdk2 inhibitory action of p27, we tested if Src inhibition could restore antiestrogen responsiveness to resistant cells.
AZD0530 is a potent, orally available dual inhibitor of Abl and Src family kinases (Ple et al., 2004) . It showed potent (<mM IC50) antiproliferative activity in 17 human cancer cell lines and inhibited growth of 6 of 13 xenograft tumor models tested. AZD0530 inhibits cell motility and invasion in vitro (Hiscox et al., 2005) and inhibits metastasis in animal models in vivo (T. Green et al., 2005, American Association for Cancer Research, abstract) .
In three different Src-activated ER-positive breast cancer lines, AZD0530 or ER-saturating doses of tamoxifen each, when given alone, caused partial cell cycle inhibition. AZD0530 together with tamoxifen increased p27, inhibited cyclin E-Cdk2, and caused G 1 arrest. In contrast, in lines lacking Src activation, addition of AZD0530 did not enhance the antiproliferative effect of tamoxifen. Our analysis showed a statistical association between low nuclear p27 and Src activation in 482 primary human breast cancers. Of 392 ER-positive cancers assayed, 127 of 339 (37%) showed Src activity scores of 2-3. This proportion is similar to the fraction of ER-positive breast cancers that manifest de novo antiestrogen resistance. These data raise the provocative possibility that Src inhibitors could restore response to tamoxifen in breast cancers with Src activation. AZD0530 has shown good bioavailability (T. Green, personal communication) and is in phase II trials for human cancers. The present data not only identify a novel mechanism whereby RTKs via Src promote p27 phosphorylation and proteolysis, they also provide a rationale for testing Src inhibitors together with antiestrogens in xenografts and to further explore their therapeutic potential in human breast cancer.
EXPERIMENTAL PROCEDURES
Cell Culture MCF-7, MDA-MB-361, BT474, T-47D, and ZR75-1 were cultured as in Cariou et al. (2000) . MCF-7 cells were depleted of estradiol using 5% charcoal-stripped FBS for 48 hr. Cell cycle entry was stimulated by estradiol (1 3 10 À8 M) and insulin (10 mg/ml). The WT and mutant p27 cDNAs were subcloned into pEYFP-C1 and transfected into MCF-7 as in Connor et al. (2003) . Fifty nanomolars of cSrc siRNA and nonspecific control oligos (Dharmacon) were transfected using Lipofectamine 2000 (Invitrogen). Activated human cSrc PCI-Src Y530F was provided by D. Fujita (University of Calgary). Human Cdk2 and cyclin E were produced from baculovirus-infected Sf9 cells as in Ciarallo et al. (2002) .
Antibodies
Antibody sources were the following: p27 (Transduction Labs and Santa Cruz), anti-PSTAIRE (Cariou et al., 2000) , Cdk2 (Santa Cruz), cyclin E1 mAbs (E12 and E172) from E. Harlow (Boston, MA), antiphosphotyrosine Ab4G10 (Upstate), Src GD11 (Upstate), and b actin (Sigma). The polyclonal apY74p27 antibody was developed by Invitrogen/Zymed using a cys-KLH-coupled peptide HKPLEGKpYEWQE for rabbit immunization and purified by column chromatography.
Assays of Immunoprecipitable and Recombinant Src
Kinase Activity Cells were lysed in 4 C NP40 lysis buffer (Cariou et al., 2000) and Src precipitated with GD11 (Upstate). IP cSrc kinase assays were as described (Egan et al., 1999) . For in vitro Src kinase reactions, 400 ng recombinant cSrc (Upstate) was reacted with (10 mg) his-p27WT or pY-p27 mutant with 2 mM ATP for 2 hr in Src kinase buffer as in Egan et al. (1999) . Radioactivity in p27 was quantitated by Molecular Dynamics PhosphorImager and ImageQuant software.
Src Effects on p27-Cyclin E-Cdk2 Binding and Cyclin E-Cdk2 Activity pY-p27 was isolated from Src kinase reactions by precipitation with mAb4G10. Recombinant cyclin E-Cdk2 was mixed with equal amounts of pY-p27 or with p27 that was either mock treated or treated with Src inactivated by PP1 and boiled for 5 min (dead Src). Cyclin E, Cdk2, and p27 immune complexes were analyzed by western blot. Cyclin E-Cdk2 activity was assayed per Cariou et al. (2000) .
Immunoblotting and Immunoprecipitation
Cells were lysed in 4 C 0.1% NP40, 1% NP40, or RIPA buffer. Western assays of cyclin E, p27, and Cdk2 and IP-western assays of cyclin E, Cdk2, and p27 complexes were as in Donovan et al. (2001) . Cellular Src was detected in p27 precipitated from 1 mg lysate. Nuclear and cytoplasmic subcellular fractionation was as described (Connor et al., 2003) .
Inducible Src Lines and Cycloheximide Chase Src Y530F cDNA was cloned into pIND (Invitrogen) and transfected into MCF-7 with an integrated pVgRXR vector (Invitrogen). Src was induced with 2 mM PA. Two clones (MCF-pINDSrc2 and MCFpINDSrc12) had no Src expression above baseline without PA but high Src levels 8-24 hr after PA. These were arrested by estrogen deprivation as above for 72 hr and 2 mM PA added or not for the last 10 hr of estrogen deprivation. Cells were then transferred to 0.1% cFBS, 10 nM estradiol added for 6 hr, and p27 t 1/2 assayed by cycloheximide. Cycloheximide 100 mg/ml was added and the decrease in p27 quantitated over time. PA alone did not alter p27 levels in parental MCF-7. For detection of T187 phosphorylated p27, at 6 hr after estrogen addition with or without prior induction of Src, cells were treated with MG132 for a further 6 hr and then pT187p27 blotted.
For Src effects on p27 stability, MDA-MB361 was treated for 6 hr with 1 mM AZD0530 prior to CHX chase. p27 was quantitated by densitometry in multiple ECL exposures of different biologic experiments and p27 t 1/2 quantitated by linear regression.
Breast Cancer Patient Population and Tumor Immunohistochemistry
The Henrietta Banting Breast Tumor Bank contains paraffin-embedded breast cancers resected between 1987 and 1997 at Women's College Hospital, Toronto, Canada. The database includes clinical and pathologic features at diagnosis and patient outcome. A tissue microarray containing more than 500 primary cancers was constructed (Kononen et al., 1998) by using three different, 0.6 mm diameter cylinders from each original tumor block. p27 immunohistochemistry was as described (Catzavelos et al., 1997) by using monoclonal p27
Kip1 antibody and biotin-labeled anti-mouse IgG, preformed avidin-biotin-peroxidase complex, and diaminobenzidine (AB) substrate. p27 was scored as percent of tumor nuclei positive (0%-24% = low p27 or R25% = high p27) (C. Catzavelos and J.S., unpublished data). Activated Src was detected by blocking with 5% H 2 O 2 and 10% normal goat serum followed by reaction with 1:33 dilution of antiphospho-cSrc (pY416-Src) (Stressgen) overnight at 4 C, reaction with biotinylated goat anti-rabbit antibody (Zymed), and then streptavidin peroxidase conjugate and diaminibenzidnine. Of 523 cases retrieved, 16 lacked Src staining, and in 25 the p27 stain was inadequate due to poor tissue fixation or no tumor on the TMA. The predominant staining intensity was scored as follows: 0, no staining; 1, weak staining; 2, moderate staining; and 3, intense staining. The mean score for three cores for each tumor was used in statistical analysis. Institutional ethics board approval was obtained prior to study initiation. Correlations between p27 and pY416-Src scores and other clinical-pathologic data in 482 tumors were assayed using Fischer's exact test to compare means and chi-square analyses to compare frequencies.
Flow Cytometric Analysis
BrdU pulse labeling and flow cytometry were as in Cariou et al. (2000) .
Cell Cycle Effects of Tamoxifen and AZD0530 AZD0530 (AstraZeneca) was used as described (Ple et al., 2004) . The lowest dose of 4-OH-TAM or AZD0530 to cause maximal cell cycle inhibition when used alone was used for assays of both drugs together. Cells were incubated with either vehicle alone, 1 mM 4-OH-TAM, 1 mM AZD0530, or both drugs together and recovered 48 hr later for flow cytometry and protein analysis.
Supplemental Data
Supplemental Data include Supplemental Experimental Procedures, three figures, and one table and can be found with this article online at http://www.cell.com/cgi/content/full/128/2/281/DC1/.
